Loading...

We've got a brand new version of Simply Wall St! Try it out

Beleave

CNSX:BE
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BE
CNSX
CA$24M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Beleave Inc. operates as a medical cannabis company in Canada. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Beleave has significant price volatility in the past 3 months.
BE Share Price and Events
7 Day Returns
-16.7%
CNSX:BE
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-76.7%
CNSX:BE
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
BE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Beleave (BE) -16.7% -23.1% -37.5% -76.7% -47% -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • BE underperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • BE underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
BE
Industry
5yr Volatility vs Market

Value

 Is Beleave undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Beleave. This is due to cash flow or dividend data being unavailable. The share price is CA$0.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Beleave's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Beleave's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:BE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.08
CNSX:BE Share Price ** CNSX (2019-09-19) in CAD CA$0.05
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Beleave.

CNSX:BE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:BE Share Price ÷ EPS (both in CAD)

= 0.05 ÷ -0.08

-0.61x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beleave is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Beleave is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Beleave's expected growth come at a high price?
Raw Data
CNSX:BE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.61x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Beleave, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Beleave's assets?
Raw Data
CNSX:BE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.02
CNSX:BE Share Price * CNSX (2019-09-19) in CAD CA$0.05
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:BE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:BE Share Price ÷ Book Value per Share (both in CAD)

= 0.05 ÷ 0.02

2.27x

* Primary Listing of Beleave.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beleave is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Beleave's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Beleave has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Beleave expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Beleave has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Beleave expected to grow at an attractive rate?
  • Unable to compare Beleave's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Beleave's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Beleave's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:BE Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:BE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:BE Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:BE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 2 -9 -34
2018-12-31 1 -13 -30
2018-09-30 1 -19 -23
2018-06-30 0 -16 -27
2018-03-31 -6 -13
2017-12-31 -3 -12
2017-09-30 -3 -11
2017-06-30 -2 -11
2017-03-31 -1 -9
2016-12-31 -1 -3
2016-09-30 0 -4
2016-06-30 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Beleave is high growth as no earnings estimate data is available.
  • Unable to determine if Beleave is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:BE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Beleave Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BE Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:BE Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.08
2018-12-31 -0.08
2018-09-30 -0.07
2018-06-30 -0.10
2018-03-31 -0.05
2017-12-31 -0.06
2017-09-30 -0.06
2017-06-30 -0.06
2017-03-31 -0.06
2016-12-31 -0.02
2016-09-30 -0.04
2016-06-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Beleave will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Beleave's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Beleave's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Beleave's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Beleave has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Beleave performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Beleave's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Beleave does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Beleave's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Beleave's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Beleave's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Beleave Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2.37 -33.78 21.32 0.01
2018-12-31 1.33 -30.12 24.70 0.09
2018-09-30 0.52 -23.37 23.16 0.09
2018-06-30 0.21 -27.03 25.46 0.15
2018-03-31 -12.64 10.44 0.15
2017-12-31 -11.95 11.60 0.08
2017-09-30 -11.00 10.74 0.08
2017-06-30 -11.22 11.10 0.02
2017-03-31 -8.55 8.49 0.02
2016-12-31 -3.19 3.10 0.03
2016-09-30 -4.15 2.63 0.05
2016-06-30 -3.07 1.51 0.04
2016-03-31 -2.99 1.42 0.06
2015-12-31 -3.10 1.41 0.12
2015-09-30 -1.23 1.03 0.10
2015-06-30 -0.93 0.95 0.03
2015-03-31 -0.51 0.38 0.08
2014-03-31 -0.84 0.75 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Beleave has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Beleave has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Beleave improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Beleave's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Beleave has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Beleave's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Beleave's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Beleave's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Beleave's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Beleave's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Beleave Company Filings, last reported 5 months ago.

CNSX:BE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 10.39 10.85 0.54
2018-12-31 20.59 10.65 1.76
2018-09-30 18.30 6.07 3.58
2018-06-30 16.44 7.23 9.55
2018-03-31 9.39 6.80 12.00
2017-12-31 10.91 5.01 13.35
2017-09-30 1.97 0.00 0.78
2017-06-30 2.72 0.00 1.39
2017-03-31 3.02 0.00 2.06
2016-12-31 2.80 0.00 1.84
2016-09-30 0.90 0.00 1.38
2016-06-30 0.57 0.00 0.16
2016-03-31 0.47 0.00 0.23
2015-12-31 1.19 -0.10 0.12
2015-09-30 1.28 0.00 0.19
2015-06-30 0.89 0.00 0.23
2015-03-31 0.87 0.00 0.23
2014-03-31 1.03 0.00 1.11
  • Beleave's level of debt (104.5%) compared to net worth is high (greater than 40%).
  • Unable to establish if Beleave's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Beleave has less than a year of cash runway based on current free cash flow.
  • Beleave has less than a year of cash runway if free cash flow continues to grow at historical rates of 95.8% each year.
X
Financial health checks
We assess Beleave's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Beleave has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Beleave's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Beleave dividends.
If you bought CA$2,000 of Beleave shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Beleave's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Beleave's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:BE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:BE Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Beleave has not reported any payouts.
  • Unable to verify if Beleave's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Beleave's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Beleave has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Beleave's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Beleave afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Beleave has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Beleave's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Panagiotakopoulos
COMPENSATION CA$1,090,000
AGE 43
TENURE AS CEO 0.6 years
CEO Bio

Mr. Vasilios Panagiotakopoulos, also known as Bill, has been Chief Executive Officer of Beleave Inc. since February 2019 and was its Chief Operating Officer since December 15, 2015. Mr. Panagiotakopoulos has applied his decades of real estate development experience to oversee the development of Beleave's flagship indoor production facility, which is producing significant yields above industry norms, and to several large expansion projects underway. As one of the founding members in 2012, he was an early mover in Canada's cannabis sector. Since then, he has contributed significantly to successfully navigating the regulatory framework to obtain a cannabis production and sales license. He is a lifelong entrepreneur with an extensive background in fundraising, investor relations, real estate development, and regulatory affairs. He has spent ten years in the Soil/Land Remediation industry as the Founder, Owner and Chief Executive Officer of Cardinal Group Inc, specializing in evaluating opportunities and helping set strategic goals in business development that has generated returns in investments, and government contracts well above industry norms. He has successfully devised and implemented numerous cost-effective bioremediation solutions that convert contaminants into harmless by-products and are environmentally safe in residential, commercial properties and salvage yards. Mr. Panagiotakopoulos served as Chief Executive Officer and President of Hamilton Solar for over five years, where he successfully developed a 250 kW Solar Tracking generating plant for the Ontario Power Authority's, Feed-In-Tariff program for renewable energy. He has built Ontario's first large scale elevated solar tracking farm on commercial land. He joined FAM two (2) years ago in capacity of Director and Chief Executive Officer. Mr. Panagiotakopoulos continues to use his resources and experience in managing construction projects to develop the project into an efficient and cost effective MMPR project. He has been Director of Beleave Inc. since December 15, 2015. He was Executive Chairman of Beleave Inc. since January 16, 2019 until March 2019.

CEO Compensation
  • Bill's compensation has increased whilst company is loss making.
  • Bill's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Beleave management team in years:

0.9
Average Tenure
  • The average tenure for the Beleave management team is less than 2 years, this suggests a new team.
Management Team

Bill Panagiotakopoulos

TITLE
CEO, MD & Director
COMPENSATION
CA$1M
AGE
43
TENURE
0.6 yrs

Roger Ferreira

TITLE
Co-Founder
COMPENSATION
CA$266K
AGE
33

Kevin Keagan

TITLE
Interim CFO
TENURE
0.6 yrs

Justin Kosalka

TITLE
Director of Operations

Myles Fontaine

TITLE
VP of Sales
TENURE
1.2 yrs

Dana Gidlow

TITLE
Head of Veteran Affairs & Community Outreach
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure of the Beleave board of directors in years:

0.5
Average Tenure
  • The average tenure for the Beleave board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jim Wasserstrom

TITLE
Independent Chairman of the Board
TENURE
0.5 yrs

Bill Panagiotakopoulos

TITLE
CEO, MD & Director
COMPENSATION
CA$1M
AGE
43
TENURE
3.8 yrs

Roger Ferreira

TITLE
Co-Founder
COMPENSATION
CA$266K
AGE
33

Kevin Keagan

TITLE
Interim CFO
TENURE
0.6 yrs

Andrew Steane

TITLE
Independent Director & Member of Advisory Board
TENURE
0.5 yrs

Amy Nederlander

TITLE
Independent Director
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • Beleave individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
12. Jul 19 Sell Roger Ferreira Individual 09. Jul 19 12. Jul 19 -280,000 CA$0.07 CA$-20,931
15. Apr 19 Sell Roger Ferreira Individual 15. Apr 19 15. Apr 19 -150,000 CA$0.10 CA$-15,000
08. Mar 19 Sell Roger Ferreira Individual 04. Mar 19 04. Mar 19 -100,000 CA$0.11 CA$-10,500
04. Feb 19 Sell Roger Ferreira Individual 04. Feb 19 04. Feb 19 -150,000 CA$0.12 CA$-17,250
07. Jan 19 Sell Roger Ferreira Individual 02. Jan 19 04. Jan 19 -300,000 CA$0.11 CA$-30,946
05. Dec 18 Sell Roger Ferreira Individual 28. Nov 18 28. Nov 18 -90,000 CA$0.13 CA$-11,700
20. Nov 18 Sell Roger Ferreira Individual 19. Oct 18 19. Oct 18 -175,000 CA$0.17 CA$-30,500
23. Oct 18 Buy Terrella Capital Ltd., Asset Management Arm Company 23. Oct 18 23. Oct 18 420,000 CA$0.13 CA$54,000
23. Oct 18 Buy Vasilios Panagiotakopoulos Individual 23. Oct 18 23. Oct 18 70,000 CA$0.12 CA$8,700
X
Management checks
We assess Beleave's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Beleave has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Beleave Inc.'s (CNSX:BE) Path To Profitability

They expect the company to post a final loss in 2020, before turning a profit of CA$7.7m in 2021. … Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is extremely buoyant. … Next Steps: This article is not intended to be a comprehensive analysis on BE, so if you are interested in understanding the company at a deeper level, take a look at BE’s company page on Simply Wall St.

Simply Wall St -

Should You Be Worried About Insider Transactions At Beleave Inc. (CNSX:BE)?

So we'll take a look at whether insiders have been buying or selling shares in Beleave Inc. … Check out our latest analysis for Beleave Beleave Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the , Gordon Harvey, sold CA$75k worth of shares at a price of CA$0.21 per share. … Over the last year we saw more insider selling of Beleave shares, than buying.

Simply Wall St -

Can We See Significant Insider Ownership On The Beleave Inc. (CNSX:BE) Share Register?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Taking a look at our data on the ownership groups (below), it's seems that. … institutions don't own many shares in the company

Simply Wall St -

Have Insiders Been Selling Beleave Inc. (CNSX:BE) Shares?

That means that an insider was happy to buy shares at above the current price … It's very possible they regret the purchase, but it's more likely they are bullish about the company … It's not at all bad to see insiders buy shares at or above current prices.

Simply Wall St -

What Kind Of Shareholders Own Beleave Inc. (CNSX:BE)?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … With a market capitalization of CA$55m, Beleave is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is Beleave Inc's (CNSX:BE) Balance Sheet Strong Enough To Weather A Storm?

Beleave Inc (CNSX:BE) is a small-cap stock with a market capitalization of CA$86.3m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Loss-Making Beleave Inc (CNSX:BE) Expected To Breakeven

Beleave Inc., together with its subsidiary, First Access Medical Inc., operates as a medical cannabis company in Canada. … The company’s loss has recently broadened since it announced a -CA$8.55m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$11.95m, moving it further away from breakeven? … The most pressing concern for investors is BE’s path to profitability – when will it breakeven

Simply Wall St -

Company Info

Description

Beleave Inc. operates as a medical cannabis company in Canada. The company cultivates and sells medical and recreational cannabis products. It also operates a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Beleave Inc. has a strategic alliance agreement with the Rollins Group Inc. to open and operate cannabis retail stores in Canada. The company sells its products through operating stores and online. Beleave Inc. is headquartered in Oakville, Canada.

Details
Name: Beleave Inc.
BE
Exchange: CNSX
Founded:
CA$24,482,564
489,651,296
Website: http://beleave.com
Address: Beleave Inc.
2030 Bristol Circle,
Suite 115,
Oakville,
Ontario, L6H 0H2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX BE New Common Shares Canadian National Stock Exchange CA CAD 31. Dec 2015
OTCPK BLEV.F New Common Shares Pink Sheets LLC US USD 31. Dec 2015
DB 4B9 New Common Shares Deutsche Boerse AG DE EUR 31. Dec 2015
Number of employees
Current staff
Staff numbers
0
Beleave employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:16
End of day share price update: 2019/09/19 00:00
Last estimates confirmation: 2018/07/31
Last earnings filing: 2019/09/04
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.